Form 8-K - Current report:
SEC Accession No. 0001193125-26-120164
Filing Date
2026-03-24
Accepted
2026-03-23 18:30:41
Documents
9
Period of Report
2026-03-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ck0001774857-20260323.htm   iXBRL 8-K 50820
  Complete submission text file 0001193125-26-120164.txt   161454

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001774857-20260323.xsd EX-101.SCH 26050
12 EXTRACTED XBRL INSTANCE DOCUMENT ck0001774857-20260323_htm.xml XML 4955
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Filer) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42513 | Film No.: 26783725
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)